vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Service Properties Trust (SVC). Click either name above to swap in a different company.
Service Properties Trust is the larger business by last-quarter revenue ($296.5M vs $281.3M, roughly 1.1× Guardant Health, Inc.). Service Properties Trust runs the higher net margin — -0.3% vs -45.7%, a 45.4% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -17.0%). Guardant Health, Inc. produced more free cash flow last quarter ($-54.2M vs $-95.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -6.1%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Medical Properties Trust, Inc. (MPT) is an international real estate investment trust (REIT) based in Birmingham, Alabama that purchases and invests in healthcare facilities and for-profit healthcare holding companies, primarily in the United States and Europe. Their property acquisitions often come in the form of sale-leaseback agreements, in which the original property owner sells the property to MPT and becomes their tenant. MPT's tenants are generally subject to long-term triple net lease...
GH vs SVC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $296.5M |
| Net Profit | $-128.5M | $-782.0K |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | -3.9% |
| Net Margin | -45.7% | -0.3% |
| Revenue YoY | 39.4% | -17.0% |
| Net Profit YoY | -15.8% | 99.0% |
| EPS (diluted) | $-1.01 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $296.5M | ||
| Q3 25 | $265.2M | $377.6M | ||
| Q2 25 | $232.1M | $404.4M | ||
| Q1 25 | $203.5M | $335.0M | ||
| Q4 24 | $201.8M | $357.0M | ||
| Q3 24 | $191.5M | $390.9M | ||
| Q2 24 | $177.2M | $412.5M | ||
| Q1 24 | $168.5M | $336.2M |
| Q4 25 | $-128.5M | $-782.0K | ||
| Q3 25 | $-92.7M | $-46.9M | ||
| Q2 25 | $-99.9M | $-38.2M | ||
| Q1 25 | $-95.2M | $-116.4M | ||
| Q4 24 | $-111.0M | $-76.4M | ||
| Q3 24 | $-107.8M | $-46.9M | ||
| Q2 24 | $-102.6M | $-73.8M | ||
| Q1 24 | $-115.0M | $-78.4M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | -3.9% | ||
| Q3 25 | -37.3% | -12.8% | ||
| Q2 25 | -45.9% | -9.2% | ||
| Q1 25 | -54.6% | -33.3% | ||
| Q4 24 | -62.4% | -19.4% | ||
| Q3 24 | -61.3% | -12.8% | ||
| Q2 24 | -56.8% | -17.1% | ||
| Q1 24 | -59.2% | -21.4% |
| Q4 25 | -45.7% | -0.3% | ||
| Q3 25 | -35.0% | -12.4% | ||
| Q2 25 | -43.0% | -9.4% | ||
| Q1 25 | -46.8% | -34.8% | ||
| Q4 24 | -55.0% | -21.4% | ||
| Q3 24 | -56.3% | -12.0% | ||
| Q2 24 | -57.9% | -17.9% | ||
| Q1 24 | -68.2% | -23.3% |
| Q4 25 | $-1.01 | $-0.01 | ||
| Q3 25 | $-0.74 | $-0.28 | ||
| Q2 25 | $-0.80 | $-0.23 | ||
| Q1 25 | $-0.77 | $-0.70 | ||
| Q4 24 | $-0.90 | $-0.46 | ||
| Q3 24 | $-0.88 | $-0.28 | ||
| Q2 24 | $-0.84 | $-0.45 | ||
| Q1 24 | $-0.94 | $-0.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $346.8M |
| Total DebtLower is stronger | $1.5B | $5.5B |
| Stockholders' EquityBook value | $-99.3M | $646.1M |
| Total Assets | $2.0B | $6.5B |
| Debt / EquityLower = less leverage | — | 8.52× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $346.8M | ||
| Q3 25 | $580.0M | $417.4M | ||
| Q2 25 | $629.1M | $63.2M | ||
| Q1 25 | $698.6M | $80.1M | ||
| Q4 24 | $525.5M | $143.5M | ||
| Q3 24 | $585.0M | $48.6M | ||
| Q2 24 | $933.7M | $14.6M | ||
| Q1 24 | $1.0B | $71.3M |
| Q4 25 | $1.5B | $5.5B | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | $5.8B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $646.1M | ||
| Q3 25 | $-354.5M | $647.9M | ||
| Q2 25 | $-305.5M | $695.9M | ||
| Q1 25 | $-250.8M | $734.6M | ||
| Q4 24 | $-139.6M | $851.9M | ||
| Q3 24 | $-60.1M | $929.0M | ||
| Q2 24 | $-1.6M | $1.0B | ||
| Q1 24 | $68.3M | $1.1B |
| Q4 25 | $2.0B | $6.5B | ||
| Q3 25 | $1.3B | $7.0B | ||
| Q2 25 | $1.3B | $6.9B | ||
| Q1 25 | $1.3B | $7.0B | ||
| Q4 24 | $1.5B | $7.1B | ||
| Q3 24 | $1.5B | $7.1B | ||
| Q2 24 | $1.6B | $7.1B | ||
| Q1 24 | $1.7B | $7.2B |
| Q4 25 | — | 8.52× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.85× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $-18.5M |
| Free Cash FlowOCF − Capex | $-54.2M | $-95.2M |
| FCF MarginFCF / Revenue | -19.3% | -32.1% |
| Capex IntensityCapex / Revenue | 9.9% | 25.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $-107.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $-18.5M | ||
| Q3 25 | $-35.4M | $98.1M | ||
| Q2 25 | $-60.3M | $-7.0K | ||
| Q1 25 | $-62.7M | $38.2M | ||
| Q4 24 | $-64.5M | $-9.7M | ||
| Q3 24 | $-51.1M | $106.2M | ||
| Q2 24 | $-94.0M | $43.8M | ||
| Q1 24 | $-30.3M | $-926.0K |
| Q4 25 | $-54.2M | $-95.2M | ||
| Q3 25 | $-45.8M | $57.9M | ||
| Q2 25 | $-65.9M | $-46.6M | ||
| Q1 25 | $-67.1M | $-23.2M | ||
| Q4 24 | $-83.4M | $-88.9M | ||
| Q3 24 | $-55.3M | $24.1M | ||
| Q2 24 | $-99.1M | $-22.3M | ||
| Q1 24 | $-37.2M | $-77.2M |
| Q4 25 | -19.3% | -32.1% | ||
| Q3 25 | -17.3% | 15.3% | ||
| Q2 25 | -28.4% | -11.5% | ||
| Q1 25 | -33.0% | -6.9% | ||
| Q4 24 | -41.3% | -24.9% | ||
| Q3 24 | -28.9% | 6.2% | ||
| Q2 24 | -55.9% | -5.4% | ||
| Q1 24 | -22.1% | -23.0% |
| Q4 25 | 9.9% | 25.9% | ||
| Q3 25 | 3.9% | 10.6% | ||
| Q2 25 | 2.4% | 11.5% | ||
| Q1 25 | 2.2% | 18.3% | ||
| Q4 24 | 9.4% | 22.2% | ||
| Q3 24 | 2.2% | 21.0% | ||
| Q2 24 | 2.9% | 16.0% | ||
| Q1 24 | 4.1% | 22.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
SVC
Segment breakdown not available.
